# Dishman Carbogen Amcis share price today (Dishman Carbogen Amcis Ltd, NSE: DCAL)

> Dishman Carbogen Amcis share price today: ₹151.09 at the NSE close on 3 November 2026, down 48.2% in a year. Dishman Carbogen Amcis (NSE: DCAL) is worth ₹2,370 crore, trades at a P/E of 130.3 and has closed between ₹136.28 and ₹257.98 over the past 52 weeks. > Dishman Carbogen Amcis Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. DCAL · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹151.09 (−48.2% in a year)
- P/E: 130.3× (higher than 89% of the last 9.1 years)
- Revenue (Jun 2026): ₹678 Cr (−4.2% on a year ago)
- Profit (Jun 2026): −₹58.0 Cr (−352.2% on a year ago)
- Operating margin: 9.0% (−11.0 points on a year ago)
- ROCE: 3%, FY26
- ROIC: 1.6%, against a 12.0% cost of capital: −10.4 points
- Profit that came in as cash: 1,031%, last 3 years

The main question: yearly earnings per share moved +2,861.9% while the share price moved −48.2%. ## What is the Dishman Carbogen Amcis share price today? Dishman Carbogen Amcis Ltd's share price was ₹151.09 at the close on 3 November 2026. It has been falling for 41 weeks. That is 17.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹136 and ₹258, and at that close it sat 12% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running. Over the last 9.1 years the share price moved −55% while the NIFTY 500 moved +157%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Dishman Carbogen Amcis this quarter? One change stood out: lowest operating margin in 8 quarters. 1. Lowest operating margin in 8 quarters Operating margin was 9% in the June 2026 quarter, against 20% a year earlier. Why: Margins fell because some customer shipments were delayed, so revenue was lower while costs stayed mostly fixed. Next results: check whether the delayed contract manufacturing shipments show up in the second half and lift that business's revenue. From the earnings call on 17 Aug 2026. ## What are Dishman Carbogen Amcis' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Dishman Carbogen Amcis reported revenue of ₹678 crore, down 4.2% from ₹708 crore a year earlier, and a loss of ₹58.0 crore, down 352.2% from ₹23.0 crore. ### Dishman Carbogen Amcis results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹678 crore | ₹708 crore | −4.2% |
| Profit | loss of ₹58.0 crore | ₹23.0 crore | −352.2% |
| Earnings per share | ₹−3.69 | ₹1.49 | −347.7% |
| Operating margin | 9.0% | 20.0% | −11.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Dishman Carbogen Amcis' management discussed these results on a call held on 17 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Dishman Carbogen Amcis share price history? Dishman Carbogen Amcis closed at ₹151.09 on 3 November 2026, down 48.2% from ₹291.80 a year earlier (31 October 2025) and down 28.9% over five years. Its highest weekly close since September 2017 was ₹383.00 on 25 January 2018. ### Dishman Carbogen Amcis share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹136.28 | +10.9% |
| 1 month ago · 1 Oct 2026 | ₹150.35 | +0.5% |
| 6 months ago · 30 Apr 2026 | ₹183.18 | −17.5% |
| 1 year ago · 31 Oct 2025 | ₹291.80 | −48.2% |
| 3 years ago · 3 Nov 2023 | ₹146.40 | +3.2% |
| 5 years ago · 4 Nov 2021 | ₹212.60 | −28.9% |
| Earliest weekly close in our records · 22 Sep 2017 | ₹334.75 | −54.9% |
| Highest weekly close since September 2017 · 25 Jan 2018 | ₹383.00 | −60.6% |
| Lowest weekly close since September 2017 · 27 Mar 2020 | ₹48.45 | +211.8% |
| 52-week high (weekly close) · 9 Jan 2026 | ₹257.98 | −41.4% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹136.28 | +10.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (480 weekly closes from 22 September 2017 to 3 November 2026.)

## What is the latest news on Dishman Carbogen Amcis? 3 Nov 2026: Dishman Carbogen Amcis closed at ₹151.09, up 10.9% on the week and up 0.5% on the month. 17 Aug 2026: Dishman Carbogen Amcis held its results call for April to June 2026. Management guided: FY27 group revenue: single-digit growth; operating margin similar to last year, potentially higher. ### Earlier

- Results for April to June 2026: Revenue down 4.2% and profit down 352.2% on a year earlier. ## What dividend does Dishman Carbogen Amcis pay? Dishman Carbogen Amcis has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Dishman Carbogen Amcis Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 11 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Dishman Carbogen Amcis management say on the latest results call? On the call for April to June 2026, held on 17 August 2026, Dishman Carbogen Amcis' management guided: FY27 group revenue: single-digit growth; operating margin similar to last year, potentially higher. > “We do expect single-digit growth in revenue, and as far as the EBITDA margin is concerned, it should be similar to what we did last year. It could be a little bit higher, but that is more or less the guidance.”
> Harshil Dalal, on the call for April to June 2026

### What management guided

- FY28-FY29 group revenue: above 10% on a year earlier, supported by India, Swiss CDMO and French operations. - FY28-FY29 group operating margin: closer to 25-26%, supported by India and CDMO growth. - FY27 India revenue: up 30-35% on a year earlier; operating margin: close to 10%. - First Switzerland-to-Bavla transfer to complete within FY27. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/7215/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 17 August 2026.)

## What to watch in Dishman Carbogen Amcis' next results? When Dishman Carbogen Amcis reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Deferred CDMO order recognition - check whether latter-half shipments reverse the segment's Q1 revenue shortfall. - What to check (from the call)
- Deferred CDMO order recognition - check whether latter-half shipments reverse the segment's Q1 revenue shortfall. - Promoter ECB execution - check direct infusion, Indian debt prepayment and finance-cost relief. - First Switzerland-to-Bavla transfer - check completion and contribution to Indian operating performance. - FDA inspections later this year - check outcomes and progression of late-phase projects toward commercial supply. ## Which stock lists is Dishman Carbogen Amcis on? Dishman Carbogen Amcis is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 2368.71079851055](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Dishman Carbogen Amcis profitable? Dishman Carbogen Amcis Ltd posted a net loss of ₹58.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹97.0 Cr. Over 15 years profit has grown 1.3% a year on average. That loss is 8.6% of the quarter's revenue. The same quarter a year earlier earned ₹23.0 Cr. 6 of the last 12 reported quarters were loss-making. Jun 2026 profit was −₹58.0 Cr, −352.2% on a year earlier. For the full year, FY26 profit was ₹97.0 Cr (+3,133.3% on the year before). Why profit moved: revenue changed −4.2% on a year earlier and the margin moved −11.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −166.0% and revenue +0.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Dishman Carbogen Amcis make, and is it growing? Dishman Carbogen Amcis Ltd reported ₹678 Cr of revenue in the Jun 2026 quarter, −4.2% on the same quarter a year earlier. Over 15 years it has grown 7.2% a year on average. The last full year, FY26, came in at ₹2,932 Cr. The last four reported quarters add to ₹2,902 Cr. FY26 revenue was ₹2,932 Cr, +8.1% on the year before. Recent pace: the last four quarters grew +0.8% on average, against 7.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +0.2%, against +9.6% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Dishman Carbogen Amcis keep? Dishman Carbogen Amcis Ltd's operating margin was 9.0% in the Jun 2026 quarter, 11.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between 11.0% and 27.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −11.0 percentage points on the year while gross margin changed −3.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Dishman Carbogen Amcis' profit turning into cash? Over the last 3 years, 1,031% of Dishman Carbogen Amcis Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹491 Cr of operating cash against ₹97.0 Cr of profit. After ₹1,463 Cr of spending on assets, free cash was −₹972 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 1,031% of profit came in as cash: the cash cycle got 455 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.5× depreciation over three years. The next section checks what that spending is building. ## Where does Dishman Carbogen Amcis' cash go? Dishman Carbogen Amcis Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 805 days in FY26, up from 350 days in FY21. It spent ₹2,359 Cr on assets over the last 3 years. Customers take 84 days to pay, and stock sits for 910 days on average. At FY26 sales of ₹2,932 Cr, each day of that cycle ties up about ₹8.0 Cr, so roughly ₹6,466 Cr is tied up in the business at any time. FY26: customers took 84 days to pay and stock sat for 910 days, about 29.9 months of sales sitting as stock, for a full cycle of 805 days, longer than FY21's 350. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 910 days. Customers pay about 84 days after that. Suppliers are paid at 189 days. Together that makes the 805-day cycle. Spending on assets: ₹2,359 Cr over the last 3 years, against ₹944 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹570 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Dishman Carbogen Amcis' P/E ratio, and how does it compare with its own history? Dishman Carbogen Amcis Ltd's P/E is 130.3×, near the high end of its own history: higher than 89% of past readings. Its usual P/E (the middle reading) is 30.6×, over 9.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹1.03. Why the multiple is where it is: over the past year earnings per share moved +2,861.9% while the price moved −48.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +1.1% a year; about −16.0% a year came from earnings growth and about +17.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Dishman Carbogen Amcis business getting better or worse? Dishman Carbogen Amcis Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Dishman Carbogen Amcis earn on its capital? Dishman Carbogen Amcis Ltd earned a ROCE of 3% in FY26. That is up from a low of 0% in FY21. Its return on capital used (ROIC) is 10.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 3.3% net margin and 0.25× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 3.3% net margin × 0.25× asset turnover × 1.78× leverage (assets divided by equity) ≈ 1.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 1.6% − 12.0% = −10.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 1.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 2.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Dishman Carbogen Amcis have too much debt? Dishman Carbogen Amcis Ltd has total debt of ₹3,076 Cr against shareholder equity of ₹6,677 Cr as of Jun 2026, so its debt is 0.46× its equity. Year by year, that ratio went from 0.33 in FY22 to 0.46 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Dishman Carbogen Amcis shareholding pattern? Foreign institutions cut their stake in Dishman Carbogen Amcis Ltd by 1.2 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 7.0% of the company. Domestic institutions moved +0.4 points over the same period, to 1.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −1.2 points over 8 quarters, to 7.0%; Domestic institutions: +0.4 points over 8 quarters, to 1.6%; Promoters: +0.0 points over 8 quarters, to 59.3%. Why the owners changed: foreign institutions drove it (−1.2 points). They reduced their stake. ## How far is Dishman Carbogen Amcis from balance-sheet trouble? For Dishman Carbogen Amcis Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Dishman Carbogen Amcis rank in its industry? 27.0 out of 100, rank 24 of 24 in Pharma - API & CRAMS, with 64% of the evidence available. Dishman Carbogen Amcis Ltd scores 27.0 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 24. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 5.6 + 5.1 + 8.8 + 7.5 = 27. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Dishman Carbogen Amcis compared with? Dishman Carbogen Amcis ranks 24 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 27.0 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. Dishman Carbogen Amcis Ltd this page DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 5.6/35 · Revenue 0.2% · Profit -80% · Operating margin change -11 points · 88% evidence Capital efficiency 5.1/25 · ROCE 3.1% · Operating margin 9% · 100% evidence Valuation 8.8/20 · P/E 125× · PEG n/a · 15% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.8% · 1 year -50.3% · 25% evidence · 1 of 12 weeks ahead Exact sum: 5.6 + 5.1 + 8.8 + 7.5 = 27 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Dishman Carbogen Amcis in size? Dishman Carbogen Amcis is the 23rd largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Morepen Laboratories, IOL Chemicals & Pharmaceuticals, SMS Pharmaceuticals, Solara Active Pharma Sciences and Hikal. Just below it: Windlas Biotech. ### Pharma - API & CRAMS companies close in size

1. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore
2. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,215 crore
3. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) ₹4,789 crore
4. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) ₹3,070 crore
5. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) ₹2,609 crore
6. Dishman Carbogen Amcis Ltd ₹2,274 crore
7. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) ₹1,808 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Knack Packaging Ltd](https://www.sectoralpha.in/stocks/knack-packaging-ltd) ₹2,276 crore · Packaging - FMCG/Consumers
2. [Mahamaya Steel Industries Ltd](https://www.sectoralpha.in/stocks/mahamaya-steel-industries-ltd) ₹2,276 crore · Steel - Rolling
3. Dishman Carbogen Amcis Ltd ₹2,274 crore
4. [Shanti Gold International Ltd](https://www.sectoralpha.in/stocks/shanti-gold-international-ltd) ₹2,266 crore · Diamond, Gems & Jewellery
5. [Sundaram Clayton Ltd](https://www.sectoralpha.in/stocks/sundaram-clayton-ltd) ₹2,258 crore · Castings, Forgings & Fastners

## What else do people ask about Dishman Carbogen Amcis? ### What is Dishman Carbogen Amcis's share price today? Dishman Carbogen Amcis Ltd's share price is ₹151.09, −48.2% over the past year. The whole company is worth ₹2,370 Cr on the market. In the last 52 weeks it traded between ₹136 to ₹258; today it is 12% of the way up from the low, 17.9% below its 200-day average (as of 3 November 2026). ### What were Dishman Carbogen Amcis's latest quarterly results? Dishman Carbogen Amcis Ltd reported revenue of ₹678 Cr and a net loss of ₹58.0 Cr for the Jun 2026 quarter. Revenue fell 4.2% and profit fell 352.2% compared with a year earlier. Earnings per share were −₹3.69 (as of 3 November 2026). ### What is Dishman Carbogen Amcis's market cap? Dishman Carbogen Amcis Ltd's market capitalisation is ₹2,370 Cr at a share price of ₹151.09. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Dishman Carbogen Amcis performing? Dishman Carbogen Amcis Ltd's share price has been falling for 41 weeks. In its latest quarter, revenue fell 4.2% and profit fell 352.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 7 weeks running (as of 3 November 2026). ### Will Dishman Carbogen Amcis's share price go up? This page does not forecast Dishman Carbogen Amcis Ltd's share price. What it shows instead: the share price is ₹151.09, and it has been falling for 41 weeks. Its P/E of 130.3× is higher than 89% of its own last 9 years (as of 3 November 2026). ### Who owns Dishman Carbogen Amcis? Promoters own 59.3% of Dishman Carbogen Amcis Ltd, foreign institutions 7.0%, domestic institutions 1.6% and the public 32.0% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 1.2 percentage points over 8 quarters (as of 3 November 2026). ### Where is Dishman Carbogen Amcis in its business cycle? Dishman Carbogen Amcis Ltd's FY26 operating margin was 19.0%, against a 11-year range of 11.0% to 27.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 9.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Dishman Carbogen Amcis story? The main question: yearly earnings per share moved +2,861.9% while the share price moved −48.2%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Dishman Carbogen Amcis a stock worth studying right now? What the numbers show: Dishman Carbogen Amcis Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Dishman Carbogen Amcis share price forecast for 2026? What management itself guided: FY27 group revenue: single-digit growth; operating margin similar to last year, potentially higher. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.